Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Down 0.4 %

NASDAQ:AKTX opened at $1.30 on Wednesday. The company has a 50-day moving average of $1.13 and a 200-day moving average of $1.70. Akari Therapeutics has a 52 week low of $0.85 and a 52 week high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.